Cibus (CBUS) Net Income (2016 - 2026)
Cibus (CBUS) posted Net Income of -$31.9 million for Q4 2025, down 31.46% sequentially from -$24.3 million in Q3 2025, and down 23.81% YoY from -$41.9 million in Q4 2024.
Cibus (CBUS) Net Income (2016 - 2026) Analysis & Trends
Cibus has reported Net Income for 10 years, with the latest figure at -$31.9 million in Q4 2025.
- Quarterly Net Income fell 23.81% year-over-year to -$31.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$132.2 million (up 53.24% YoY) and the FY2025 annual result came in at -$132.2 million, up 53.24% from the prior year.
- Net Income declined to -$31.9 million in Q4 2025 per CBUS's latest filing, from -$24.3 million in the prior quarter.
- Over five years, Net Income peaked at -$2.5 million in Q2 2022 and troughed at -$277.2 million in Q4 2023.
- A 5-year average of -$39.9 million and a median of -$22.4 million in 2023 frame the typical range for Net Income.
- The sharpest annual moves came in 2023 and 2024: Net Income plunged 9671.17% in 2023, then soared 90.69% in 2024.
- Over 5 years, Net Income stood at -$7.1 million in 2021, then soared by 59.8% to -$2.8 million in 2022, then slumped by 9671.17% to -$277.2 million in 2023, then jumped by 90.69% to -$25.8 million in 2024, then declined by 23.81% to -$31.9 million in 2025.
- According to Business Quant data, Net Income over the past three periods registered -$31.9 million, -$24.3 million, and -$26.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | -22.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.15 Mn |
| Dec 31, 2025 | -31.95 Mn |
| Sep 30, 2025 | -24.30 Mn |
| Jun 30, 2025 | -26.56 Mn |
| Mar 31, 2025 | -49.39 Mn |
| Dec 31, 2024 | -25.80 Mn |
| Sep 30, 2024 | -201.46 Mn |
| Jun 30, 2024 | -28.48 Mn |
| Mar 31, 2024 | -26.97 Mn |
| Dec 31, 2023 | -277.21 Mn |
| Sep 30, 2023 | -34.53 Mn |
| Jun 30, 2023 | -20.51 Mn |
| Mar 31, 2023 | -5.39 Mn |
| Dec 31, 2022 | -2.84 Mn |
| Sep 30, 2022 | -5.95 Mn |
| Jun 30, 2022 | -2.49 Mn |
| Mar 31, 2022 | -5.62 Mn |
| Dec 31, 2021 | -7.06 Mn |
| Sep 30, 2021 | -7.31 Mn |
| Jun 30, 2021 | -4.81 Mn |